{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:24:59Z","timestamp":1793975099594,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"The Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"University Grants Committee Research Grants Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tumour Virus Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.tvr.2026.200346","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:23:21Z","timestamp":1782573801000},"page":"200346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting EBV-associated gastric cancer by lytic induction therapy with nanatinostat"],"prefix":"10.1016","volume":"22","author":[{"given":"Man","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Yee","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Skora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuk Yu","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Tin-Yun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Man","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"El-Guindy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-6124","authenticated-orcid":false,"given":"Kwok Wai","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tvr.2026.200346_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.4448","article-title":"The role of epstein-barr virus in epithelial malignancies","volume":"235","author":"Tsao","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.tvr.2026.200346_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","article-title":"Epstein-barr virus-associated gastric cancer: a distinct subtype","volume":"495","author":"Yang","year":"2020","journal-title":"Cancer Lett."},{"issue":"2024","key":"10.1016\/j.tvr.2026.200346_bib3","article-title":"The viral etiology of EBV-Associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape","volume":"15","author":"Salnikov","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.tvr.2026.200346_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.gtc.2022.05.001","article-title":"Gastric cancer: emerging trends in prevention, diagnosis, and treatment","volume":"51","author":"Norwood","year":"2022","journal-title":"Gastroenterol. Clin. N. Am."},{"issue":"10494","key":"10.1016\/j.tvr.2026.200346_bib5","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.tvr.2026.200346_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101260","article-title":"Therapeutic approaches to epstein-barr virus cancers","volume":"56","author":"Soldan","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.tvr.2026.200346_bib7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fonc.2020.00600","article-title":"Targeting epstein-barr virus in nasopharyngeal carcinoma","volume":"10","author":"Hau","year":"2020","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.tvr.2026.200346_bib8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/cancers12082142","article-title":"Lytic induction therapy against epstein-barr virus-associated malignancies: past, present, and future","volume":"12","author":"Yiu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.tvr.2026.200346_bib9","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with epstein-barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.tvr.2026.200346_bib10","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for epstein-barr virus-driven tumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.tvr.2026.200346_bib11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia Ankara encoding epstein-barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.tvr.2026.200346_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/1078-0432.CCR-24-2814","article-title":"First-in-human clinical trial of a small-molecule EBNA1 inhibitor, VK-2019, in patients with epstein-barr-positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies","volume":"31","author":"Colevas","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"482","key":"10.1016\/j.tvr.2026.200346_bib13","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks epstein-barr virus latent infection and tumor growth","volume":"11","author":"Messick","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.tvr.2026.200346_bib14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s10120-021-01193-6","article-title":"EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of epstein-barr virus-associated gastric cancer","volume":"24","author":"Soldan","year":"2021","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.tvr.2026.200346_bib15","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1038\/s41467-024-48031-8","article-title":"Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-Associated epithelial cancers","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.tvr.2026.200346_bib16","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1182\/bloodadvances.2023010330","article-title":"Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-Positive lymphoid malignancies: a phase 1b\/2 study","volume":"7","author":"Haverkos","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.tvr.2026.200346_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.tvr.2026.200346_bib18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"4","key":"10.1016\/j.tvr.2026.200346_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G","article-title":"Establishment and characterization of human gastric carcinoma cell lines","volume":"70","author":"Park","year":"1997","journal-title":"Int. J. Cancer"},{"issue":"Pt 3","key":"10.1016\/j.tvr.2026.200346_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1099\/vir.0.045237-0","article-title":"Characterization of naturally epstein-barr virus-infected gastric carcinoma cell line YCCEL1","volume":"94","author":"Kim","year":"2013","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.tvr.2026.200346_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s13402-012-0073-9","article-title":"Establishment and characterization of six human gastric carcinoma cell lines, including one naturally infected with epstein-barr virus","volume":"35","author":"Ku","year":"2012","journal-title":"Cell. Oncol."},{"issue":"12","key":"10.1016\/j.tvr.2026.200346_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145994","article-title":"Identification of novel small organic compounds with diverse structures for the induction of epstein-barr virus (EBV) lytic cycle in EBV-Positive epithelial malignancies","volume":"10","author":"Choi","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tvr.2026.200346_bib23a","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1038\/s41467-018-06889-5","article-title":"Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma","volume":"9","author":"Lin","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.tvr.2026.200346_bib23b","article-title":"Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer","volume":"7","author":"Wong","year":"2025","journal-title":"JHEP Rep."},{"issue":"12","key":"10.1016\/j.tvr.2026.200346_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"6","key":"10.1016\/j.tvr.2026.200346_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"issue":"3","key":"10.1016\/j.tvr.2026.200346_bib26","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"issue":"4","key":"10.1016\/j.tvr.2026.200346_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.molcel.2020.03.025","article-title":"MYC controls the epstein-barr virus lytic switch","volume":"78","author":"Guo","year":"2020","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.tvr.2026.200346_bib28","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.24945","article-title":"Suberoylanilide hydroxamic acid induces viral lytic cycle in epstein-barr virus-positive epithelial malignancies and mediates enhanced cell death","volume":"126","author":"Hui","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.tvr.2026.200346_bib29","doi-asserted-by":"crossref","first-page":"17314","DOI":"10.18632\/oncotarget.1168","article-title":"The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF\u03baB signalling pathway","volume":"6","author":"Smith","year":"2015","journal-title":"Oncotarget"},{"issue":"7 Supplement","key":"10.1016\/j.tvr.2026.200346_bib30","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1158\/1538-7445.AM2023-6226","article-title":"Abstract 6226: therapeutic vulnerability of MTAP-Deleted nasopharyngeal carcinoma by MAT2A inhibitors","volume":"83","author":"Chan","year":"2023","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.tvr.2026.200346_bib31","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/jmv.24870","article-title":"Cytolytic virus activation therapy and treatment monitoring for epstein-barr virus associated nasopharyngeal carcinoma in a mouse tumor model","volume":"89","author":"Novali\u0107","year":"2017","journal-title":"J. Med. Virol."},{"issue":"W1","key":"10.1016\/j.tvr.2026.200346_bib32","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"10.1016\/j.tvr.2026.200346_bib33","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2023012183","article-title":"Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma","volume":"8","author":"Sharma","year":"2024","journal-title":"Blood Adv."}],"container-title":["Tumour Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666679026000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666679026000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:29:55Z","timestamp":1793971795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666679026000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":34,"alternative-id":["S2666679026000108"],"URL":"https:\/\/doi.org\/10.1016\/j.tvr.2026.200346","relation":{},"ISSN":["2666-6790"],"issn-type":[{"value":"2666-6790","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting EBV-associated gastric cancer by lytic induction therapy with nanatinostat","name":"articletitle","label":"Article Title"},{"value":"Tumour Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvr.2026.200346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"200346"}}